Credo Technology Group Stock (NASDAQ: CRDO)

Dernières nouvelles pour Credo Technology Group (NASDAQ:CRDO) Stock

Credo Technology Group

Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.

Credo Technology Group Holding Ltd - Ordinary Shares

Credo Technology Group Holding Ltd

Cerrado Gold Inc

WIIM

YALA

Yalla Group shares are trading lower following Q1 reported financial results.

X Financial shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

UBS analyst Robin Farley maintains Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) with a Buy and raises the price target from $301 to $311.

News

Price Target

Analyst Ratings

UBS Maintains Buy on Royal Caribbean Gr, Raises Price Target to $311

Management

ROLR

High Roller Appoints Adam Felman As CFO; Succeeds Matt Teinert

UBS analyst Jay Sole maintains Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) with a Neutral and raises the price target from $32 to $36.

BBWI

UBS Maintains Neutral on Bath & Body Works, Raises Price Target to $36

Wearable Devices Ltd. (the "Company" or "Wearable Devices") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDS#NASDAQ">WLDS</a>, WLDSW))), a technology growth company specializing in artificial intelligence ("AI")-powered touchless sensing wearables, today announced the release of a new Mudra Link update for Mac and Windows users. The latest version introduces significant enhancements, including support for gesture-based Media Keys control, a firmware update for improved stability, a streamlined onboarding experience, and various bug fixes.
The new Media Control feature introduces gesture-based media control to the Mudra Link neural wristband, bringing a modern twist to a familiar digital convenience. For years, media keys on keyboards have offered users quick access to playback controls like play, pause, and volume. Mudra Link now reimagines that experience - allowing users to assign natural hand gestures such as a tap or pinch to those same functions, without the need for buttons, screens, or physical contact.

WLDS

Wearable Devices Announces The Release Of A New Mudra Link Update For Mac And Windows Users

Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) is <a target="_blank" href="https://www.benzinga.com/topic/tsmc" rel="noreferrer noopener">bolstering its collaborations</a> with Taiwan Semiconductor Manufacturing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) and original design manufacturers (ODMs) in Taiwan.
Qualcomm has historically been a leading customer of Taiwan Semiconductor and will continue to be, as the Taipei Times <a target="_blank" href="https://www.taipeitimes.com/News/biz/archives/2025/05/20/2003837162" rel="noreferrer noopener">reported</a> on Tuesday, citing Qualcomm chief Cristiano Amon ahead of the annual Computex trade show.
Amon told the Taipei Times that Qualcomm was a leading fabless semiconductor designer.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45411148/taiwan-semiconductor-commits-15-billion-to-chip-expansion-approves-dividend-amid-rising-global-demand" rel="noreferrer noopener">Taiwan Semiconductor Commits $15 Billion To Chip Expansion, Approves Dividend</a>
The company ships about 40 billion mobile and AI-enabled chipsets annually, and Taiwan Semiconductor is its primary manufacturing partner.
Amon highlighted Taiwan&#8217;s strength in the personal computer (PC) ecosystem and Qualcomm&#8217;s growing ties with Taiwan&#8217;s PC sector through collaboration with domestic players like Quanta Computer Inc. and Compal Electronics Inc.
Taiwan&#8217;s chip designer MediaTek will also start using Taiwan Semiconductor&#8217;s latest 2-nm chipmaking technology by September 2025, Nikkei Asia <a target="_blank" href="https://asia.nikkei.com/Business/Tech/Semiconductors/MediaTek-to-use-TSMC-s-2-nm-chip-tech-to-stay-in-AI-race2" rel="noreferrer noopener">reported</a> on Tuesday, citing MediaTek CEO Rick Tsai at Computex.
Tsai said the technology will serve its high-volume devices.
Taiwan Semiconductor is a leading contract chipmaker for companies like Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>). The stock has surged over 26% in the last 12 months thanks to the AI frenzy. However, the stock has dropped over 4% year-to-date as the Trump administration&#8217;s tariff policies have taken a toll on the stock, similar to its semiconductor peers.
Recently, Taiwan Minister of Economic Affairs J.W. Kuo said he did not expect the U.S. tariffs to <a target="_blank" href="https://www.benzinga.com/government/regulations/25/05/45508534/taiwan-minister-shrugs-off-us-tariffs-says-taiwan-semiconductor-will-thrive-while-samsung-takes-the-hit" rel="noreferrer noopener">affect Taiwanese manufacturers</a>, thanks to its semiconductor ecosystem. Kuo expects&nbsp;Taiwan Semiconductor to maintain its moat over the next decade, citing that any tariff upsurge would primarily affect U.S. customers instead of the foundry.
Price Action:&nbsp;TSM stock is down 0.87% to $191.82 premarket at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/media/25/05/45496055/intels-next-gen-ai-tech-steals-the-show-at-computex-2025" target="_blank" rel="noreferrer noopener">Intel&#8217;s Next-Gen AI Tech Steals The Show At Computex 2025</a></li>
</ul>
Photo by wakamatsu via Shutterstock

Tech

Media

AAPL

NVDA

QCOM

Taiwan Semiconductor, Qualcomm, MediaTek Team Up To Power Next-Gen Mobile And AI Chips

On May 20, 2025, Union Bankshares, Inc. (the "Company") and its wholly-owned subsidiary, Union Bank (the "Bank"), entered into an Equity Distribution Agreement (the "Agreement") with Piper Sandler &amp; Co. as sales agent (the "Agent"), pursuant to which the Company may sell from time to time through the Agent, shares of the Company's common stock, par value $2.00 (the "Common Stock"), having an aggregate gross sale price of up to $40,000,000 (the "Offering"). Sales of Common Stock, if any, under the Agreement may be made in any transactions that are deemed to be "at the market offerings" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the "Securities Act"). In addition, with our prior consent and subject to the terms we may establish, the Agent may also sell the Common Stock by any other method permitted by law, including privately negotiated transactions.
Under the Agreement, the Company will set the parameters for the sale of the Common Stock from time to time, including the number of shares to be issued, the time period during which sales are requested to be made, limitations on the number of shares that may be sold by the Agent in any one trading day and any minimum price below which sales may not be made. The Company has agreed to pay the Agent a commission equal to 3% of the gross sales price of the Common Stock sold in the Offering. The Agent has agreed to use its commercially reasonable efforts to sell the shares of common stock in the Offering, subject to the terms of the Agreement.
The Agreement contains customary representations, warranties and covenants of the Company and the Bank, and conditions to the Agent's obligations to sell the Common Stock in the Offering. The Company and the Bank have agreed jointly and severally to provide to the Agent customary indemnification and contribution rights. The Company will also reimburse the Agent for certain specified expenses in connection with establishing and maintaining the Offering.
The Company has no obligation to sell any Common Stock under the Agreement, and may at any time suspend solicitation and sales in the Offering. The Agreement may be terminated at any time, for any reason, by either the Company or the Agent upon prior notice to the other party.

Offerings

Union Bankshares Enters $40M At-the-Market Equity Distribution Agreement With Piper Sandler For Potential Common Stock Sales

<ul>
<li>Red Hat OpenShift generally available on Oracle Cloud Infrastructure (OCI)</li>
<li>Oracle Cloud Infrastructure adds Red Hat OpenShift support for Dedicated Regions and Oracle Government Cloud Regions and OpenShift on Compute Cloud@Customer</li>
<li>Red Hat OpenShift now compatible with many Oracle software applications</li>
</ul>
Red Hat, the world's leading provider of open source solutions, and Oracle today announced an expanded collaboration to break down barriers to hybrid cloud adoption. This latest joint effort delivers a more consistent, cloud-native foundation that is critical for next-generation workloads including AI by bringing Red Hat Enterprise Linux and Red Hat OpenShift support to more deployment options on <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.oracle.com%2Fcloud%2F&amp;esheet=54257230&amp;newsitemid=20250520218168&amp;lan=en-US&amp;anchor=Oracle+Cloud+Infrastructure&amp;index=1&amp;md5=764144fcdc5688b6556332dff40e38b7">Oracle Cloud Infrastructure</a> (OCI), including government, sovereign, and distributed cloud services.

ORCL

Red Hat And Oracle Announce Expanded Collaboration To Break Down Barriers To Hybrid Cloud Adoption; Red Hat OpenShift Now Compatible With Many Oracle Software Applications

Barclays analyst Adrienne Yih maintains Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) with a Overweight and raises the price target from $59 to $73.

URBN

Barclays Maintains Overweight on Urban Outfitters, Raises Price Target to $73

PEGA

Pegasystems shares are trading higher following announcements that the company will join the S&P Midcap 400.

JE Cleantech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCSE#NASDAQ">JCSE</a>) reported $14.11 million in sales this quarter. This is a 3.24 percent increase over sales of $13.67 million the same period last year.

Earnings

JCSE

JE Cleantech Hldgs FY24 EPS $0.00, Sales $14.11M Up From $13.67M YoY

GDS Holdings shares are trading higher after the company reported better-than-expected Q1 EPS results.

Barclays analyst Theresa Chen maintains Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) with a Overweight and lowers the price target from $206 to $178.

TRGP

Barclays Maintains Overweight on Targa Resources, Lowers Price Target to $178

Health Care

General

Guardant Health Launches Guardant Hereditary Cancer Test

VIPS

Vipshop Holdings shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results.

New all-in-one IVT kit can deliver up to 2X more mRNA and up to&nbsp;85%&nbsp;lower dsRNA compared to other kits on the market through streamlined mRNA synthesis with efficient capping, increased yield, reduced dsRNA, and enhanced performance
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.trilinkbiotech.com%2F&amp;esheet=54257039&amp;newsitemid=20250520267814&amp;lan=en-US&amp;anchor=TriLink+BioTechnologies&amp;index=1&amp;md5=d0e424440efc37a9e9b38a277158eddb">TriLink BioTechnologies</a>&reg; (TriLink&reg;), a Maravai&reg; LifeSciences company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>), is fueling the future of mRNA research &mdash; starting with a significant donation to top academic labs across the U.S. and Europe.
The donation commemorates the launch of TriLink&#39;s first&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftrilinkbiotech.com%2Fcleancap-ivt-kits&amp;esheet=54257039&amp;newsitemid=20250520267814&amp;lan=en-US&amp;anchor=mRNA+synthesis+kit&amp;index=2&amp;md5=10cb95d3eb0cfb8f9c96258074fbfeac">mRNA synthesis kit</a>&nbsp;featuring CleanCap&reg; capping technology, an all-in-one kit with its innovative products in one box at a competitive price. Seven academic institutions will receive ten kits each that can yield up to a combined 250mg of capped mRNAs, enabling and encouraging further discovery and development in the field of mRNA-based medicine.
Labs in academic institutions, such as those listed below, have gratefully accepted the kits donated by TriLink to drive progress in RNA therapeutics and build a strong future for the field.
<ul>
<li>The Center for RNA Therapeutics at Houston Methodist Research Institute (HMRI)</li>
<li>The Center of RNA Technologies and Therapeutics at UC San Diego</li>
<li>The University Medical Center Utrecht</li>
<li>The University of Oxford</li>
<li>Yale School of Medicine</li>
</ul>
The new&nbsp;in vitro&nbsp;transcription (IVT) kit will simplify mRNA synthesis and elevate IVT by leveraging TriLink&#39;s high-performing products where users can expect up to 2X more mRNA yield and up to&nbsp;85%&nbsp;lower dsRNA compared to other kits on the market. The IVT kit components include:
<ul>
<li><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.trilinkbiotech.com%2Fcleancap-reagent-ag-3-ome.html&amp;esheet=54257039&amp;newsitemid=20250520267814&amp;lan=en-US&amp;anchor=CleanCap%26%23174%3B+AG+%283%26%238242%3B+OMe%29&amp;index=3&amp;md5=b347179ae00eb2c566bb7ffc698a0def">CleanCap&reg; AG (3&prime; OMe)</a>&nbsp;for co-transcriptional capping</li>
<li><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.trilinkbiotech.com%2Fcleanscribe-rna-polymerase.html&amp;esheet=54257039&amp;newsitemid=20250520267814&amp;lan=en-US&amp;anchor=CleanScribe%26%238482%3B+RNA+Polymerase&amp;index=4&amp;md5=10f50085c672dd825897927874d4807c">CleanScribe&trade; RNA Polymerase</a>&nbsp;for dsRNA reduction</li>
<li><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.trilinkbiotech.com%2Fbrowse%2Fnucleoside-triphosphates-nucleotides&amp;esheet=54257039&amp;newsitemid=20250520267814&amp;lan=en-US&amp;anchor=Nucleotides+including+N1-methylpseuouridine&amp;index=5&amp;md5=6d9fb4fe33940c3648a6d1443b2a762a">Nucleotides including N1-methylpseuouridine</a>&nbsp;for enhanced mRNA performance, and</li>
<li><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fgo.trilinkbiotech.com%2Fcleanscript-technote&amp;esheet=54257039&amp;newsitemid=20250520267814&amp;lan=en-US&amp;anchor=CleanScript%26%23174%3B+IVT&amp;index=6&amp;md5=4f9c217670825905028a1a55813f06d4">CleanScript&reg; IVT</a>&nbsp;for increased yield.</li>
</ul>
&quot;This launch brings together a powerful suite of novel IVT components that reflect TriLink&#39;s years of experience and innovation in mRNA synthesis,&quot; shared Justin Barbosa, Vice President &amp; General Manager of TriLink Discovery. &quot;By offering all these components in a single kit, we&#39;re simplifying researcher workflow and accelerating discovery. The addition of CleanScript IVT optimization also ensures our customers can generate more high-quality mRNA per reaction &mdash; maximizing both efficiency and performance.&quot;
The kit comes ready to use and is the only commercially available IVT kit featuring CleanCap AG (3&prime; OMe), which is a modified version of the original CleanCap AG with over&nbsp;95%&nbsp;capping efficiency to improve protein expression. CleanCap co-transcriptional capping provides advantages over legacy capping methods of ARCA or enzymatic by streamlining mRNA manufacturing with fewer steps and handling, thereby saving researchers time and resources.
&quot;This is an important product launch, where we are bringing several technology and process improvements to an integrated IVT kit,&quot; said Trey Martin, CEO of Maravai. &quot;Today we are also making a statement about our commitment to the future of mRNA science. By donating the first new kits to top academic institutions across the U.S. and Europe, we are investing in the next generation of mRNA innovators and empowering groundbreaking research that could lead to the therapies of tomorrow. We are honored to help our field continue to evolve and improve through new innovations and process improvements.&quot;

MRVI

Trilink Biotechnologies Releases Its First mRNA Synthesis Kit With CleanCap Capping Technology

- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window by reducing toxicity
- Following recent IND clearance from U.S. FDA, ALX2004 will enter clinical studies mid-year 2025 with initial safety data anticipated in 1H 2026
- Trials evaluating the Company's lead investigational therapy, CD47-blocker evorpacept, in breast and colorectal cancers planned to initiate in mid-2025 with multiple key inflection points from evorpacept and ALX2004 development programs anticipated in 2026
SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, provides an overview of the clinical development program for its highly-differentiated antibody-drug conjugate (ADC), ALX2004, at the Company's R&amp;D webcast event today. ALX Oncology leadership will discuss the unique design profile, preclinical data and clinical development plans for ALX2004, a potential best- and first-in-class ADC for the treatment of epidermal growth factor receptor (EGFR)-expressing solid tumors, that is planned to enter Phase 1 studies in mid-year 2025.

Biotech

ALXO

ALX Oncology Unveils Clinical Development Plans For ALX2004, A ADC Targeting EGFR-Expressing Tumors, With Phase 1 Trials Set For Mid-2025 Following FDA IND Clearance And Initial Data Expected In 1H 2026, While Advancing CD47-Blocker Evorpacept In Breast And Colorectal Cancer Trials Also Starting Mid-2025

QBTS

D-Wave Quantum shares are trading higher after the company announced it launched its Advantage2 quantum system to address problems in optimization, AI, and materials simulation.

DUOT

Duos Technologies Appoints Craig Nixon As Board Chairman

Press Releases

Credo's PCIe® Retimer Successfully Passes PCI-SIG® Compliance

Credo Reports Third Quarter of Fiscal Year 2025 Financial Results

Credo Showcasing AEC PCIe Products for AI Scaling at NVIDIA GTC 2025

Credo Files AEC Patent Infringement Complaint Against Amphenol, Molex, TE Connectivity, and Volex with United States International Trade Commission

Credo and XConn to Showcase Seamless GPU Cluster at NVIDIA GTC

WPG Americas Accelerates High-Speed Connectivity Solutions through Credo Partnership

Credo to Showcase AI Scale Out Fabric Featuring Credo Optical DSPs at OFC 2025

Credo Named a Winner of the 2025 Top Workplaces USA Award

Credo Unveils the Lark Family - Setting a New Benchmark for Low-Power 800G Optical DSPs

Credo Schedules Fourth Quarter and Fiscal Year 2025 Financial Results Conference Call

CRDO

Analog Devices

Astera Labs

Advanced Micro Devices, Inc. - Common Stock

Advanced Micro Devices

Arm Holdings plc - American Depositary Shares

ARM Holdings

ASE Technology Holding Co., Ltd. American Depositary Shares (each representing Two Common Shares)

Comments

Credo Technology Group

Actualités

Dernières nouvelles pour Credo Technology Group (NASDAQ:CRDO) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL